Detection of clonality and genetic alterations in endometrial pipelle biopsy and its surgical specimen counterpart

Laboratory Investigation

Volumn 76, Issue 1, 1997, Pages 109-116

  Esteller, Manel ^a   García, Angel ^a   Martínez Palones, Josep M ^a   Xercavins, Jordi ^a   Reventós, Jaume ^a  

^a HOSPITAL MATERNO INFANTIL VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL CLONE; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR CLONING; POINT MUTATION; PRIORITY JOURNAL;

ADENOCARCINOMA; ALLELES; ATROPHY; BIOPSY; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; DNA METHYLATION; DNA PRIMERS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; GENES, RAS; GENITAL DISEASES, FEMALE; HETEROZYGOTE DETECTION; HUMANS; HYPERPLASIA; PHOSPHOGLYCERATE KINASE; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; X CHROMOSOME;

EID: 0031018505     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, and Belmont JW (1992). Methylation of Hpa II and Hha I sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet 51:1229-1239.
2. Arnold A, Staunton CE, Kim HG, Gaz RD, and Kronenberg HM (1988). Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. N Engl J Med 318: 658-662.
3. Averette HE, Steren A, and Nguyen N (1993). Screening in gynecologic cancer. Cancer 72:1043-1049.
4. Berchuck A, Rodriguez G, Kinney RB, Soper JT, Dodge RK, Clarke-Pearson DL, and Bast RC (1991). Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164:15-21.
5. Berrozpe G, Schaeffer J, Peinado MA, Real FX, and Perucho M (1994). Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer 58:185-191.
6. Boring CC, Squires TS, and Tong T (1993). Cancer statistics. CA Cancer J Clin 43:7-26.
7. Boyd J (1994). Molecular genetics of human endometrial carcinoma. In: Khan SA and Stancel GM, editors. Protooncogenes and growth factors in steroid hormone induced growth and differentiation. Boca Raton, FL: CRC Press, 193-205.
8. Brison O (1993). Gene amplification and tumor progression. Biochim Biophys Acta 1155:25-41.
9. Caduff RF, Johnston CM, and Frank TS (1995). Mutations of the Ki-ras oncogene in carcinoma of the endometrium. Am J Pathol 146:182-188.
10. Chambers JT and Chambers SK (1992). Endometrial sampling: When? Where? Why? With what? Clin Obstet Gynecol 35:28-39.
11. Enomoto T, Fujita M, Inoue M, Rice JM, Nakajima R, Tanizawa O, and Nomura T (1993). Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 53:1883-1888.
12. Esteller M, Garcia A, Martínez-Palones JM, Cabero A, and Reventós J (1995a). Detection of c-erbB2/neu and fibroblast growth factor-3/INT-2 but not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction. Cancer 75:2139-2146.
13. Esteller M, Martínez-Palones JM, Garcia A, Xercavins J, and Reventós J (1995b). High rate of MDR-1 and heterogeneous pattern of MRP expression without gene amplification in endometrial cancer. Int J Cancer 63:798-803.
14. Fearon ER, Hamilton SR, and Vogelstein B (1987). Clonal analysis of human colorectal tumors. Science 238:193-197.
15. Friend SH, Dryja TP, and Weinberg RA (1988). Oncogenes and tumor-supressing genes. N Engl J Med 318:6118-622.
16. Frye RA, Benz CC, and Liu E (1989). Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene 4:1153-1157.
17. Gilbert J, Norris MD, Haber M, Kavallaris M, Marshall GM, and Stewart BW (1993). Determination of N-myc gene amplification by differential polymerase chain reaction. Mol Cell Probe 7:227-234.
18. Gilliland DG, Blanchard KL, Levy J, Perrin S, and Bunn HF (1991). Clonality in myeloproliferative disorders: Analysis by means of the polymerase chain reaction. Proc Natl Acad Sci USA 88:6848-6852.
19. Gottesman MM and Pastan I (1993). Biochemistry of multidrug resistance mediated by the multidrug resistance gene. Annu Rev Biochem 62:385-427.
20. Gramlich TL, Fritsch CR, Maurer D, Eberle M, and Gansler TS (1994). Differential polymerase chain reaction assay of cyclin D1 gene amplification in esophageal carcinoma. Diagn Mol Pathol 3:255-259.
21. Grimes DA (1982). Diagnostic dilatation and curettage: A reappraisal. Am J Obstet Gynecol 142:1-6.
22. Harris CC (1993). p53: At the crossroads of molecular carcinogenesis and risk assesment. Science 262:1980-1981.
23. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, and Podratz KC (1992). HER-2/NEU expression: A major pronostic factor in endometrial cancer. Gynecol Oncol 47:179-185.
24. Honda T, Kato H, Imamura T, Gima T, Nishida J, Sasaki M, Hoshi K, Sato A, and Wake N (1992). Involvement of p53 gene mutations in human endometrial carcinomas. Int J Cancer 53:963-967.
25. Jovanovic AS, Boynton KA, and Mutter GL (1996). Uteri of women with endometrial carcinoma contain a histopathological spectrum of monoclonal putative precancers, some with microsatellite instability. Cancer Res 56:1917-1921.
26. Kahn SM, Jiang W, Culbertson TA, Weinstein IB, Williams GM, Tomita N, and Ronai Z (1991). Rapid and sensitive nonradioactiive detection of mutant K-ras genes via "enriched" PCR amplification. Oncogene 6:1079-1083.
27. Kihana T, Hamada K, Inoue Y, Yano N, Iketani H, Murao SI, Ukita M, and Matsuura S (1995). Mutation and allelic loss of the p53 gene in endometrial carcinoma-incidence and outcome in 92 surgical patients. Cancer 76:72-78.
28. Knudson AR (1973). Mutation and human cancer. Adv Cancer Res 17:317-352.
29. Kohler MF, Nishii H, Humphrey PA, Sasaki H, Marks J, Bast RC, and Marks JR (1992). Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52:1622-1627.
30. Kraus MH, Popescu NC, Amsbaugh SC, and King CR (1987). Overexpression of the EGF receptor-related proto-oncogene erbB2 in human mammary tumor cell lines by different molecular mechanisms, EMBO J 298:859-863.
31. Mizuuchi H, Nasim S, Kudo R, Silverberg SG, Greenhouse S, and Garrett CT (1992). Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res 52:2777-2781.
32. Mutter GL, Chaponot ML, Fletcher JA (1995). A polymerase chain reaction assay for non-random X chromosome inactivation identifies monoclonal endometrial cancers and pre-cancers. Am J Pathol 146:501-508.
33. Neubauer A, Neubauer B, He M, Effert P, Iglehart D, Frye RA, and Liu E (1992). Analysis of gene amplification in archival tissue by differential polymerase chain reaction. Oncogene 7:1019-1025.
34. Nicolaides A, Huang YQ, Li JJ, Zhang WG, and Friedman-Kien (1994). Gene amplification and multiple mutations of the K-ras oncogene in Kaposi's sarcoma. Anticancer Res 14: 921-926.
35. Noguchi S, Motomura K, Inaji H, Imaoka S, and Koyama H (1992). Clonal analysis of human breast cancer by means of the polymerase chain reaction. Cancer Res 52:6594-6597.
36. Nowell PC (1988). Molecular events in tumor development. N Engl J Med 319:575-577.
37. Okamoto A, Sameshima Y, Yamada Y, Teshima S, Terashima Y, Terada M, and Yokota J (1991). Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus. Cancer Res 51:5632-5636.
38. Ramzy I and Mody DR (1991). Gynecologic citology: Practical considerations and limitations. Clin Lab Med 11:271-292.
39. Risinger JL, Dent GA, Ignar-Trowbrige D, McLachlan JA, Tsao MS, Senterman M, and Boyd J (1992). p53 gene mutations in human endometrial carcinoma. Mol Carcinog 5:250-253.
40. Sasaki H, Nishii H, Takahashi H, Tada A, Furusato M, Terashima Y, Siegal GP, Parker SL, Kohler MF, Berchuck A, and Boyd J (1993). Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res 53:1906-1910.
41. Sawada M, Azuma C, Hashimoto K, Noguchi S, Ozaki M, Saji F, and Tanizawa S (1994). Clonal analysis of human gynecologic cancers by means of the polymerase chain reaction. Int J Cancer 58:492-496.
42. Schreiber G and Dubeau L (1990). C-myc proto-oncogene amplification detected by polymerase chain reaction in archival human ovarian carcinomas. Am J Pathol 137:653-658.
43. Stovall TG, Photopoulos GJ, Poston WM, Ling FW, and Sandles LG (1991). Pipelle endometrial sampling in patients with known endometrial carcinoma. Obstet Gynecol 77:954-956.
44. Vogelstein B, Fearon ER, Hamilton SR, and Feinberg AP (1985). Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors. Science 227: 642-645.
45. Whetsell LH, Ringer DP, and Schaefer FV (1994). Molecular approach to rapid assessment of p53 tumor supressor mutations in esophageal tumors from stained histological slides. Diagn Mol Pathol 3:132-141.
46. Zaman GJR, Versantvoort CHM, Smit JJM, Eijdems EWHM, De Haas M, Smith AJ, Broxterman HJ, Mulder NH, De Vries EGE, Baas F, and Borst P (1993). Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 53:1747-1750.